2-[3-(N,N-diethylamino)-2-hydroxypropylaminocarbonyl]-3-methoxy-1-phenylindole | 85793-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[3-(N,N-diethylamino)-2-hydroxypropylaminocarbonyl]-3-methoxy-1-phenylindole
• 英文别名: Eproxindine；N-[3-(diethylamino)-2-hydroxypropyl]-3-methoxy-1-phenylindole-2-carboxamide
• CAS: 85793-29-9
• 化学式: C₂₃H₂₉N₃O₃
• 分子量: 395.502
• InChiKey: JZQYAVBXJCQSOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  66.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[3-(N,N-diethylamino)-2-hydroxypropylaminocarbonyl]-3-methoxy-1-phenylindole 生成 N-[3-(diethylamino)-2-hydroxypropyl]-3-hydroxy-1-phenylindole-2-carboxamide
  参考文献：
  名称：

  OHLENDORF, HEINRICH-WILHELM;KAUPMANN, WILHELM;KUHL, URICH;BUSCHMANN, GERD+

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Methoxy-1-phenyl-1H-indole-2-carboxylic acid 生成 2-[3-(N,N-diethylamino)-2-hydroxypropylaminocarbonyl]-3-methoxy-1-phenylindole
  参考文献：
  名称：

  OHLENDORF, HEINRICH-WILHELM;KAUPMANN, WILHELM;KUHL, URICH;BUSCHMANN, GERD+

  摘要：

  DOI：

文献信息

• 1-Phenyl-2-aminocarbonylindole compounds, preparation thereof and
  申请人：Kali-Chemie Pharma GmbH

  公开号：US04803198A1

  公开（公告）日：1989-02-07

  New 1-phenyl-2-aminocarbonylindole compounds are described which have the general formula I ##STR1## where R.sub.1 is a hydrogen atom, or a lower alkyl, alkenyl, cycloalkylalkyl radical, R.sub.2 is a hydrogen atom or a lower alkyl radical, R.sub.3 is a hydrogen or halogen atom, or a lower alkyl, hydroxyl or lower alkoxy radical, R.sub.4 is a hydrogen or halogen atom, or a lower alkyl, hydroxyl or lower alkoxy radical, or, if R.sub.3 is a hydrogen atom, R.sub.4 may be a nitro or trifluoromethyl radical, or R.sub.3 and R.sub.4 together denote a methylenedioxy or ethylenedioxy radical, R.sub.5 has the meanings given for R.sub.3, R.sub.6 has the meanings given for R.sub.4, R.sub.7 is a hydrogen atom or, if R.sub.5 and R.sub.6 are lower alkoxy radicals, R.sub.7 may also be a lower alkoxy radical, R.sub.8 and R.sub.9 are each a hydrogen atom or a lower alkyl radical or, together with the nitrogen atom, form a heterocyclic group, and Z is an alkylene chain which is optionally substituted by hydroxyl. The compounds have pharmaceutical properties, in particular antiarrhythmic properties. The compounds may be in the form of the free bases or acid addition salts. Pharmaceutical compositions containing these compounds are described as is a method of preparing them. Valuable intermediates for the production of these compounds and methods of preparing the intermediates are also described.

  描述了具有通式I的新1-苯基-2-氨基甲酰吲哚化合物，其中R.sub.1是氢原子，或者是较低的烷基、烯基、环烷基烷基基团，R.sub.2是氢原子或较低的烷基基团，R.sub.3是氢原子或卤素原子，或者是较低的烷基、羟基或较低的烷氧基团，R.sub.4是氢原子或卤素原子，或者是较低的烷基、羟基或较低的烷氧基团，或者，如果R.sub.3是氢原子，R.sub.4可以是硝基或三氟甲基基团，或者R.sub.3和R.sub.4一起表示亚甲二氧基或乙二氧基基团，R.sub.5具有R.sub.3给出的含义，R.sub.6具有R.sub.4给出的含义，R.sub.7是氢原子或者，如果R.sub.5和R.sub.6是较低的烷氧基基团，R.sub.7也可以是较低的烷氧基基团，R.sub.8和R.sub.9分别是氢原子或较低的烷基基团，或者与氮原子一起形成杂环基团，Z是一条可以由羟基取代的烷基链。这些化合物具有药理学性质，特别是抗心律失常性质。这些化合物可以是自由碱或酸盐的形式。描述了含有这些化合物的药物组合物，以及其制备方法。还描述了用于生产这些化合物的有价值的中间体以及制备这些中间体的方法。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and
  申请人：Kali-Chemie Pharma GmbH

  公开号：US04924004A1

  公开（公告）日：1990-05-08

  New 1-phenyl-2-aminocarbonylindole compounds are described which have the general formula I ##STR1## where R.sub.1 is a hydrogen atom, or a lower alkyl, alkenyl, cycloalkyl or cycloalkylalkyl radical, R.sub.2 is a hydrogen atom or a lower alkyl radical, R.sub.3 is a hydrogen or halogen atom, or a lower alkyl, hydroxyl or lower alkoxy radical, R.sub.4 is a hydrogen or halogen atom, or a lower alkyl, hydroxyl or lower alkoxy radical, or, if R.sub.3 is a hydrogen atom, R.sub.4 may be a nitro or trifluoromethyl radical, or R.sub.3 and R.sub.4 together denote a methylenedioxy or ethylenedioxy radical, R.sub.5 has the meanings given for R.sub.3, R.sub.6 has the meanings given for R.sub.4, R.sub.7 is a hydrogen atom or, if R.sub.5 and R.sub.6 are lower alkoxy radicals, R.sub.7 may also be a lower alkoxy radical, R.sub.8 and R.sub.9 are each a hydrogen atom or a lower alkyl radical or, together with the nitrogen atom, form a heterocyclic group, and Z is a alkylene chain which is optionally substituted by hydroxyl. The compounds have pharmacological properties, in particular antiarrhythmic properties. The compounds may be in the form of the free base or acid addition salts. Pharmaceutical compositions containing these compounds are described as is a method of preparing them. Valuable intermediates for the production of these compounds and methods of preparing the intermediates are also described.

  本发明涉及新的1-苯基-2-氨基甲酰吲哚化合物，其具有通式I ##STR1## 其中R.sub.1是氢原子或较低的烷基，烯基，环烷基或环烷基烷基基团，R.sub.2是氢原子或较低的烷基基团，R.sub.3是氢原子或卤素原子，或较低的烷基，羟基或较低的烷氧基基团，R.sub.4是氢原子或卤素原子，或较低的烷基，羟基或较低的烷氧基基团，或者，如果R.sub.3是氢原子，则R.sub.4可以是硝基或三氟甲基基团，或者R.sub.3和R.sub.4一起表示亚甲二氧基或乙二氧基基团，R.sub.5具有R.sub.3的给定含义，R.sub.6具有R.sub.4的给定含义，R.sub.7是氢原子或者，如果R.sub.5和R.sub.6是较低的烷氧基基团，则R.sub.7也可以是较低的烷氧基基团，R.sub.8和R.sub.9分别是氢原子或较低的烷基基团，或者与氮原子一起形成杂环基团，Z是可以被羟基取代的烷基链。这些化合物具有药理学性质，特别是抗心律失常性质。这些化合物可以是自由碱或酸加成盐的形式。本发明还描述了含有这些化合物的药物组合物以及制备它们的方法。本发明还描述了用于生产这些化合物的有价值的中间体以及制备中间体的方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。